Uniphar (LON:UPR) Rating Reiterated by Deutsche Bank Aktiengesellschaft

Uniphar (LON:UPR)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday, Digital Look reports. They presently have a GBX 310 ($4.08) target price on the stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 36.56% from the stock’s previous close.

Uniphar Price Performance

LON:UPR opened at GBX 227 ($2.98) on Wednesday. The firm has a market cap of £619.76 million, a PE ratio of 1,621.43 and a beta of 0.77. Uniphar has a 12 month low of GBX 178 ($2.34) and a 12 month high of GBX 256 ($3.37). The company has a quick ratio of 0.60, a current ratio of 0.88 and a debt-to-equity ratio of 114.50. The company’s 50-day moving average price is GBX 216.44 and its two-hundred day moving average price is GBX 222.68.

Uniphar Company Profile

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally. The company operates through three divisions: Medtech, Pharma, and Supply Chain & Retail. The Medtech division offers outsourced sales; and marketing, distribution, and support services to medical device manufacturers.